Docetaxel as second-line treatment in 23 patients with advanced non-small cell lung cancer / 中国癌症杂志
China Oncology
;
(12)2001.
Article
Dans Chinois
| WPRIM
| ID: wpr-539820
ABSTRACT
Purpose:
To evaluate the effectiveness and safety of the second-line treatment in patients with advanced non small cell lung cancer(NSCLC).Methods:
23 patients with histologically and /or cytologically confirmed advanced NSCLC were treated with docetaxel(taxotere) 75mg/m 2 on d1 every 3 weeks. All patients had received prior platinum-containing chemotherapy and relapsed or progressed after receiving one prior chemothergpy regimen.Results:
23 patients were available for evaluation partial response (PR) was 17% (4/23), stable disease(SD)and progressive disease(PD) was 57% (13/23) and 26% (6/23), respectively, there was no complete response (CR). The response rate was 17% (4/23) and the median survival of all patients was 9 months .one -year survival rate was 39% (9/23) . Hematologic toxicity was the main side effect, and they were well tolerated.Conclusions:
Taxotere as second-line treatment of NSCLC is effective, and toxicity is tolerated.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Chinois
Texte intégral:
China Oncology
Année:
2001
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS